CRANBURY, N.J. - Palatin Technologies (NYSE:PTN), Inc. (NYSE American: PTN), a biopharmaceutical firm with a market capitalization of $23.22 million, has announced a new funding round through a ...

Pursuant to the completion of the sale of Vyleesi’s worldwide rights for female sexual dysfunction to Cosette Pharmaceuticals for up to $171M in December 2023, Palatin (PTN) did not record any ...

CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...

Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is ...

Carl Spana; President, Chief Executive Officer, Director; Palatin Technologies Inc Stephen Wills; Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer, Secretary ...

(RTTNews) - Palatin Technologies, Inc. (PTN), a biopharmaceutical company, on Thursday announced the completion of its Phase 2 BMT-801 clinical study evaluating the combination of MC4R ...

Fair Value Adjustment Loss: $8.1 million for the quarter ended December 31, 2024. Palatin Technologies Inc (PTN) reported a significant decrease in net cash used in operations, from $10.5 million ...